AF
DFTX

Arrow Financial’s Definium Therapeutics DFTX Stock Holding History

Arrow Financial’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-66
Closed -$376 – 264
2024
Q3 		$376 Hold
66
– – ﹤0.01% 333
2024
Q2 		$476 Hold
66
– – ﹤0.01% 329
2024
Q1 		$620 Hold
66
– – ﹤0.01% 326
2023
Q4 		$242 Hold
66
– – ﹤0.01% 345
2023
Q3 		$207 Hold
66
– – ﹤0.01% 342
2023
Q2 		$236 Hold
66
– – ﹤0.01% 322
2023
Q1 		$209 Hold
66
– – ﹤0.01% 322
2022
Q4 		$0 Hold
66
– – ﹤0.01% 335
2022
Q3 		$0 Sell
66
-1
-1% -$10 ﹤0.01% 346
2022
Q2 		$1K Hold
67
– – ﹤0.01% 348
2022
Q1 		$1K Hold
67
– – ﹤0.01% 351
2021
Q4 		$1K Hold
67
– – ﹤0.01% 331
2021
Q3 		$2K Hold
67
– – ﹤0.01% 321
2021
Q2 		$3K Buy
+67
New +$3.52K ﹤0.01% 322

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrow Financial's DFTX Position: Q4 2024 in Review

Arrow Financial sold out of Definium Therapeutics (DFTX) in Q4 2024, closing a stake of 66 shares — an estimated $376 sold.

Arrow Financial first reported a position in DFTX in Q2 2021 and held it in 14 quarters. The position peaked at $3K in Q2 2021. 172 funds tracked by Wall St. Rank hold DFTX as of Q4 2024.

  • Arrow Financial reported no remaining Definium Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Arrow Financial sold 66 Definium Therapeutics shares in Q4 2024, an estimated $376.
  • Arrow Financial first reported a position in Definium Therapeutics in Q2 2021 and held it in 14 quarters.
  • Arrow Financial's Definium Therapeutics position peaked at $3K in Q2 2021.
  • 172 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2024.

Based on Arrow Financial's 13F filing for Q4 2024, filed 14 Feb 2025.